Y-mabs enters into partnership with Uruguayan firm to launch cancer drugs in South America
Danish biotech firm Y-mabs Therapeutics has closed a Latin American distribution contract for the company's two cancer drugs.
BY ALBERT RØNNING-ANDERSSON AND ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Y-mabs Therapeutics has found distribution partners in South America for its two pediatric cancer drugs.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Y-mabs files for EU approval for pediatric cancer drug
For subscribers
FDA requires more data from Y-mabs
For subscribers
